Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shire
Age
6–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
6-12 years old
ADHD diagnosis
ADHD-RS-IV minimum score of 28
CGI-S score \> or = 4
You may not be if
Current, controlled or uncontrolled, comorbid psychiatric diagnosis
Condition or illness which represent inappropriate risk to subject
Known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems, exercise-related cardiac events, or clinically significant bradycardia; orthostatic hypotension or controlled or uncontrolled hypertension
Use of prohibited medication that have CNS effects or affect cognitive performance
History of alcohol or substance abuse within 6 months
Current use of medication that affect BP or heart rate
Significantly overweight
Weight of less than 55 lbs
Known allergy to SPD503
Abnormal urine drug and alcohol screen
Clareo Health | Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
